CASE REPORT
Hyperandrogenism as a clinical manifestation of familial partial lipodystrophy type 2 in an adolescent female patient
More details
Hide details
1
Departments of Pediatrics and Pediatric Endocrinology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
Submission date: 2024-06-17
Final revision date: 2024-11-30
Acceptance date: 2024-12-27
Publication date: 2025-03-24
Corresponding author
Ewa Błaszczyk
Departments of Pediatrics and Pediatric Endocrinology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
Pediatr Pol 2025;61(1):97-101
KEYWORDS
TOPICS
ABSTRACT
We present a case report of a girl with significant hyperandrogenism with accompanying metabolic disorders. In the physical examination, attention was drawn to tall stature, excessive body mass with a muscular build, broad shoulders and a narrow pelvis, low timbre of voice, acne lesions, enlarged mandible, hirsutism (19 points on the Ferriman-Gallwey scale), and elevated blood pressure. Substantial hyperandrogenemia was noted, with a significantly increased testosterone level and elevated levels of adrenal androgens. Based on steroid metabolome analysis from 24-hour urine collection, congenital adrenal hyperplasia was ruled out. Dyslipidemia and impaired glucose tolerance with hyperinsulinism in the oral glucose tolerance test were found. Magnetic resonance imaging of the abdomen and pelvis revealed a fatty liver and overgrowth of muscles and mesentery with adipose tissue. Whole exome sequencing was performed, revealing the presence of a known, pathogenic molecular variant, c.1394G > A, in the LMNA gene, associated with the occurrence of familial partial lipodystrophy.
REFERENCES (21)
1.
Martin KA, Rox Anderson R, Jeffrey Chang R, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2018; 103: 1233-1257.
2.
Sharma A, Welt CK. Practical approach to hyperandrogenism in women. Med Clin North Am 2021; 105: 1099.
3.
Hickey M, Doherty DA, Atkinson H, et al. Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. Hum Reprod 2011; 26: 1469-1477.
4.
Gambineri A, Fanelli F, Prontera O, et al. Prevalence of hyperandrogenic states in late adolescent and young women: epidemiological survey on Italian high-school students. J Clin Endocrinol Metab 2013; 98: 1641-1650.
5.
Esquivel-Zuniga MR, Kirschner CK, McCartney CR, Burt Solorzano CM. Non-PCOS hyperandrogenic disorders in adolescents. Semin Reprod Med 2022; 40: 42-52.
6.
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47.
7.
Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol 2010; 203: 201.e1-201.e5.
8.
Ibáñez L, Oberfield SE, Witchel S, et al. An International Consortium Update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr 2017; 88: 371-395.
9.
Williams RM, Ong KK, Dunger DB. Polycystic ovarian syndrome during puberty and adolescence. Mol Cell Endocrinol 2013; 373: 61-67.
11.
Witchel SF, Oberfield S, Rosenfield RL, et al. The diagnosis of polycystic ovary syndrome during adolescence. Horm Res Paediatr 2015; 83: 376-389.
12.
Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 2006; 91: 2100-2104.
13.
Knebel B, Müller-Wieland D, Kotzka J. Lipodystrophies – disorders of the fatty tissue. Int J Mol Sci 2020; 21: 1-15.
14.
Vu NP, Tran HT, Vu NB, et al. Severe loss of adipose tissue in a Vietnamese lipodystrophy patient caused by LMNA p.G465D mutation: a first clinical characterization and two-year follow-up. J Pediatr Endocrinol Metab 2022; 35: 1206-1210.
15.
Speckman RA, Garg A, Du F, Bennett L, et al. Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the global C-terminal domain of lamin A/C. Am J Hum Genet 2000; 66: 1192-1198.
16.
Haque WA, Oral EA, Dietz K, Bowcock AM, Agarwal AK, Garg A. Risk factors for diabetes in familial partial lipodystrophy, Dunnigan variety. Diabetes Care 2003; 26: 1350-1355.
18.
Araújo-Vilar D, Santini F. Diagnosis and treatment of lipodystrophy: a step-by-step approach. J Endocrinol Invest 2019; 42: 61-73.
19.
Bagias C, Xiarchou A, Bargiota A, Tigas S. Familial partial lipodystrophy (FPLD): Recent insights. Diabetes Metab Syndr Obes 2020; 13: 1531-1544.
21.
Mosbah H, Donadille B, Vatier C, et al. Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins). Orphanet J Rare Dis 2022; 17: 170.